News & Views
Eurostars Grant to support GBM Treatment Project
Oct 02 2022
A consortium of industry and research partners including French Biotech Covalab, focused on recombinant proteins and antibodies for diagnostics and therapeutics; CimCure (Netherlands), Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland, have received a €1.06M ($1.08M) grant from EUREKA Eurostars towards development of a new treatment against glioblastoma. A total budget of €2.24M ($2.28M), including investments from the partners is available to support the project ‘Optimal Synergistic Immunotherapy Strategy (OpSIS)’, which will take place over 3 years.
OpSIS aims to will develop a combination therapy using CimCure’s iBoost vaccines and CAR-T cells against GBM and to then provide a validation for translation of this strategy in GBM patients. This project strives to demonstrate the efficacy, long-term persistence and synergistic ability of combining GMB-targeting CAR-T cells with tumour vasculature-targeting vaccines.
“We are excited to bring our extensive expertise in antibody engineering to the OpSIS project. Additionally, our platforms in molecular biology, immunology and bioproduction will support the preclinical validation of therapeutic molecules and we can use our know-how in anticancer immunotherapy for this unique combination therapy project in oncology,” said Dr Saïd El Alaoui, CEO and founder of Covalab.”
“The Eurostars funding of OpSIS provides a unique opportunity to test our iBoost vaccines in combination with other immunotherapy approaches. We see an important innovation in testing this combination strategy in glioblastoma, a disease with a dismal clinical outcome. The collaboration with Covalab, the University of Zurich and Amsterdam UMC is unique and promises major achievements,” said Diederik Engbersen, CEO at CimCure.
“Immunotherapy for brain tumous has been a major research focus at the University of Zurich. We are delighted to join forces with colleagues from the Netherlands and France, OpSIS will enable the development of novel treatment approaches by combining innovative immunotherapeutic strategies, to be explored in various clinically relevant models,” said Dr. Patrick Roth, University Hospital Zurich, Department of Neurology.
More information online
Digital Edition
Labmate UK & Ireland 49.2 - March 2024
March 2024
In This Edition Articles - Choosing the right LIMS for your lab: Four key considerations - Pay increases to continue but staff focus on security and training - Building a global culture of...
View all digital editions
Events
Mar 26 2024 Milan, Italy
Mar 27 2024 Lyon, France
Microbiology Society Annual Conference 2024
Apr 08 2024 Edinburgh 2024
Apr 09 2024 Munich, Germany
Apr 10 2024 Helsinki, Finland